Flag of the European Union EU Clinical Trials Register Help

Clinical trials for False Memory Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    194 result(s) found for: False Memory Syndrome. Displaying page 3 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-010067-16 Sponsor Protocol Number: CN156018 Start Date*: 2009-07-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal ...
    Medical condition: ALZHEIMER DISEASE
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000702-30 Sponsor Protocol Number: 18.021 Start Date*: 2019-10-30
    Sponsor Name:Odense University Hospital
    Full Title: Fibromyalgia and Naltrexone: The FINAL study
    Medical condition: Fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-004679-36 Sponsor Protocol Number: 05 2015-001 Start Date*: 2006-12-13
    Sponsor Name:Laboratoire HRA Pharma
    Full Title: Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
    Medical condition: Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10014155 Ectopic corticotrophin syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003053-25 Sponsor Protocol Number: 1466 Start Date*: 2012-06-18
    Sponsor Name:Research and Enterprise Department
    Full Title: A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson’s disease who have fallen.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000054-28 Sponsor Protocol Number: OLIGOTREAT Start Date*: 2023-06-02
    Sponsor Name:Klinikum der Universität München
    Full Title: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000381-39 Sponsor Protocol Number: KCL/DS/MEM/1 Start Date*: 2005-08-24
    Sponsor Name:King's College London
    Full Title: Efficacy and Safety of Memantine Hydrochloride, a low affinity antagonist to N-Methyl-D-Aspartate (NMDA) type receptors, in the prevention of cognitive decline and disease progression in older peop...
    Medical condition: Cognitive decline and dementia in Down's syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000369-42 Sponsor Protocol Number: WA43380 Start Date*: 2023-03-15
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, INTERNATIONAL, MULTICENTER, RANDOMISED OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB VERSUS MMF IN PATIENTS WITH CHILDHOOD ONSET IDIOPATHIC NEPHROTIC SYNDROME
    Medical condition: Childhood Onset Idiopathic Nephrotic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10029164 Nephrotic syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000222-11 Sponsor Protocol Number: 1 Start Date*: 2016-02-04
    Sponsor Name:University College London
    Full Title: A phase II, randomised, double-blind, placebo- controlled, multi-site, parallel group clinical trial to examine ketamine as a pharmacological treatment for alcohol dependence in an alcohol dependen...
    Medical condition: Severe Alcohol Use Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004873 10001585 Alcohol abuse chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003200-14 Sponsor Protocol Number: JR-141-GS31 Start Date*: 2022-05-16
    Sponsor Name:JCR Pharmaceuticals Co., Ltd.
    Full Title: A Phase III study of JR-141 in Mucopolysaccharidosis type II (Hunter Syndrome) patients.
    Medical condition: Mucopolysaccharidosis type II
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003115-20 Sponsor Protocol Number: 848041001 Start Date*: 2018-02-19
    Sponsor Name:Erasmus Medical Center Rotterdam
    Full Title: Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: a prospective randomised multicenter double-blind placebo-controlled clinical trial
    Medical condition: Delirium
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004873 10012224 Delirium toxic LLT
    21.1 100000004873 10000702 Acute delirium LLT
    21.1 100000004873 10042275 Subacute delirium LLT
    21.0 100000004873 10012220 Delirium due to a general medical condition LLT
    21.0 100000004873 10012226 Delirium, cause unknown LLT
    21.0 100000004873 10071313 Hypoactive delirium LLT
    21.0 100000004873 10071314 Hyperactive delirium LLT
    21.0 100000004873 10071315 Mixed delirium LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003817-32 Sponsor Protocol Number: LOLA-Merz:WMDHP39937 Start Date*: 2013-01-08
    Sponsor Name:Imperial College London
    Full Title: Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate
    Medical condition: Hepatic Encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000821-29 Sponsor Protocol Number: SPD503-401 Start Date*: 2020-11-19
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...
    Medical condition: Attention-deficit/hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Trial now transitioned) SE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) PT (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-001392-21 Sponsor Protocol Number: P018.087 Start Date*: 2018-09-25
    Sponsor Name:Leiden University Medical Center
    Full Title: A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythematosus
    Medical condition: systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10042947 Systemic lupus erythematosus synd LLT
    20.0 100000004857 10029142 Nephritis systemic lupus erythematosus LLT
    21.1 100000004859 10042948 Systemic lupus erythematosus syndrome aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002976-28 Sponsor Protocol Number: CCNP520A2202J Start Date*: 2017-05-16
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease ...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) FI (Prematurely Ended) IS (Completed) PT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008555-41 Sponsor Protocol Number: INSULA Start Date*: 2011-05-26
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Comparative study of the effect of intranasal insulin on memory deficits in type 2 diabetes and early Alzheimer´s dementia (INSULA)
    Medical condition: Early Alzheimer´s dementia (eAD), type 2 diabetes mellitus with amnestic mild cognitive impairment (T2D-aMCI), healthy controls (Co)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    17.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001564-21 Sponsor Protocol Number: GN09CP301 Start Date*: 2011-09-19
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Towards Onset Prevention of COGnitive decline in adults with Down syndrome (the TOP-COG study)
    Medical condition: Alzheimer's disease Down syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    14.0 10010331 - Congenital, familial and genetic disorders 10013616 Down's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001414-10 Sponsor Protocol Number: 202100076 Start Date*: 2021-03-30
    Sponsor Name:University Medical Center Groningen
    Full Title: Vaccine response against SARS-CoV-2 in patients with primary Sjögren’s syndrome
    Medical condition: Primary Sjögren's syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002476-40 Sponsor Protocol Number: 17-APN-01 Start Date*: 2019-05-07
    Sponsor Name:CHU de Nice
    Full Title: Personalized Medicine for Membranous Nephropathy PMMN
    Medical condition: Idiopathic Membranous Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002601-38 Sponsor Protocol Number: D5010C00009 Start Date*: 2015-01-29
    Sponsor Name:Eli Lilly and Company
    Full Title: A 24-Month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker and Pharmacokinetics Study of AZD3293 in Early Alzheimer’s Disease (...
    Medical condition: Early Alzheimer’s Disease (mild cognitive impairment due to AD (ie, prodromal AD) and mild dementia of the Alzheimer’s type)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Prematurely Ended) DE (Completed) ES (Completed) HU (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006949-13 Sponsor Protocol Number: BRD/06/162 Start Date*: 2007-10-16
    Sponsor Name:University College London
    Full Title: A multi-centre exploratory study to evaluate the efficacy of the dopamine receptor agonist rotigotine in the treatment of hemispatial neglect and motor deficits following stroke.
    Medical condition: Hemispatial neglect and motor deficits following right-hemisphere stroke.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 21:22:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA